Aspen Capital Group (ACG) | Growth Equity Firm & Technology Investors

Aspen Capital Group takes great pride in helping our partner companies build leading businesses that will succeed for years to come

Aspen Capital Group focuses on partnering with founders and entrepreneurs to help them execute on their companies’ growth strategies. We maintain a long-term investment horizon that focuses on maximizing the value creation potential of each partner company. Our unique capital base allows for significant flexibility in structuring and determining the hold period for each investment.

Learn More

Long-term Perspective

We have a successful track record of partnering with companies to drive long-term growth.

Value Creation

We focus on identifying and continuously driving towards key initiatives to achieve and maintain market leadership.

Strategic Partnerships

We help companies assemble world class Boards of Directors, Executive Teams and Strategic Partners.

How We Add Value

“XG Sciences has been working with Aspen Capital since early 2013. They closed their first investment quickly after signing a term sheet and have been a trusted partner ever since. In addition to participating in every financing since then, either directly or through one of their affiliates, they have been instrumental in helping to refine our focus and attract world class partners, Board Members and investors. This has helped us significantly increase our valuation and positioned us well to pursue an Initial Public Offering in the next 12-24 months. Steven Jones has been an investor for nine years and a Board Member for the last six years, and he is just as involved today as he was in the beginning.“

Philip Rose, Ph.D - Chief Executive Officer of XG Sciences, Inc.

“Steve Jones of Aspen Capital was instrumental in the growth and development of NeoGenomics. Aspen closed its first investment in 2003 and continued to invest for years as the Company required growth capital. In addition, Steve was deeply involved in helping NeoGenomics refine its business model and strategy, and execute many strategic initiatives. Today, NeoGenomics is a recognized leader in Oncology Diagnostics with a market capitalization over $2 billion and Steve remains a trusted member of our Board.”

Douglas VanOort - Chairman and CEO, NeoGenomics, Inc. (NASDAQ: NEO)

Press Releases

CLARA analytics Raises $25M in Series B Funding https://secureservercdn.net/198.71.233.44/010.8a0.myftpupload.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 Aspen Capital Group Aspen Capital Group https://secureservercdn.net/198.71.233.44/010.8a0.myftpupload.com/wp-content/themes/movedo/images/empty/thumbnail.jpg May 21, 2020 May 21, 2020

May 21, 2020

CLARA analytics Raises $25M in Series B Funding

SANTA CLARA, Calif. — CLARA analytics (“CLARA”), the leading provider of artificial intelligence (AI) technology in the commercial insurance industry, today announced that it closed $25 million in Series B funding, bringing its total funding to $36.5 million. The round was led by growth equity firm Aspen Capital Group with participation from Series A lead Oak HC/FT and additional investors. CLARA…

Naples capital firm helps its portfolio of companies with hands-on strategy

Hands-on approach goes a long way for firm investing some $150 million in promising companies. by: Beth Luberecki, Business Observer For Steve Jones, making an investment in a company requires more than just an infusion of cash. “I call our firm more of a partner capitalist,” says the chairman and managing partner of Naples-based growth…

John Gordy and John Haesler Join Aspen Capital Group as Principals

Naples, Florida – December 10, 2019 – Aspen CapitalTM, a growth equity firm that partners with founders and entrepreneurs to build industry-leading technology and tech-enabled businesses, is excited to announce that John Gordy and John Haesler have joined as Principals. John and John are an excellent fit with Aspen’s long-term investment strategy and focus. They…